Sera Prognostics (NASDAQ:SERA) Posts Earnings Results, Misses Expectations By $0.03 EPS

Sera Prognostics (NASDAQ:SERA) posted its quarterly earnings results on Wednesday. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.03), FiscalAI reports. Sera Prognostics had a negative net margin of 56,385.97% and a negative return on equity of 41.02%. The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.07 million.

Sera Prognostics Price Performance

NASDAQ:SERA traded up $0.03 during midday trading on Wednesday, reaching $2.02. 27,687 shares of the company traded hands, compared to its average volume of 52,816. The firm has a market capitalization of $79.10 million, a price-to-earnings ratio of -3.11 and a beta of 0.96. The company has a fifty day moving average price of $2.00 and a 200 day moving average price of $2.13. Sera Prognostics has a twelve month low of $1.56 and a twelve month high of $3.95.

Insiders Place Their Bets

In other Sera Prognostics news, CEO Zhenya Lindgardt sold 20,755 shares of the stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $2.08, for a total value of $43,170.40. Following the sale, the chief executive officer directly owned 871,999 shares of the company’s stock, valued at $1,813,757.92. This trade represents a 2.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 27,755 shares of company stock valued at $57,840 over the last quarter. 11.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Sera Prognostics

Several institutional investors have recently modified their holdings of the company. Qube Research & Technologies Ltd acquired a new stake in shares of Sera Prognostics in the 2nd quarter worth about $92,000. Captrust Financial Advisors boosted its stake in Sera Prognostics by 20.0% during the 2nd quarter. Captrust Financial Advisors now owns 602,277 shares of the company’s stock valued at $1,668,000 after purchasing an additional 100,366 shares during the period. Corient Private Wealth LLC grew its position in Sera Prognostics by 73.9% in the 2nd quarter. Corient Private Wealth LLC now owns 100,000 shares of the company’s stock worth $277,000 after purchasing an additional 42,500 shares during the last quarter. Vanguard Group Inc. grew its position in Sera Prognostics by 4.6% in the 3rd quarter. Vanguard Group Inc. now owns 1,217,190 shares of the company’s stock worth $3,725,000 after purchasing an additional 54,008 shares during the last quarter. Finally, Squarepoint Ops LLC increased its stake in shares of Sera Prognostics by 8.9% in the third quarter. Squarepoint Ops LLC now owns 93,063 shares of the company’s stock valued at $285,000 after purchasing an additional 7,643 shares during the period. Institutional investors own 54.64% of the company’s stock.

Analysts Set New Price Targets

SERA has been the topic of a number of research reports. Craig Hallum began coverage on shares of Sera Prognostics in a report on Thursday, June 4th. They set a “buy” rating and a $6.00 target price on the stock. Weiss Ratings lowered shares of Sera Prognostics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $5.50.

Sera Prognostics Company Profile

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.